Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Approves First Dissolving Stent for U.S. Patients

By Matthew Perrone, AP Health Writer | July 5, 2016

Close up image of Absorb (Credit: Abbott Laboratories)

A medical implant that slowly dissolves into the body could be the answer to long-standing safety concerns with devices used to treat clogged arteries.

But not so fast, say experts.

Abbott Laboratories’ newly-approved Absorb stent comes with one important caveat: it hasn’t yet been shown to be safer than older metal implants.

The Food and Drug Administration approved the device Tuesday for patients with coronary artery disease, the artery-narrowing condition that causes about 370,000 U.S. deaths each year, according to government figures. The new stent is made of a plastic-like material that’s designed to gradually dissolve over three years.

Currently-available stents are permanent, mesh-wire tubes that hold open arteries after a procedure used to clear fatty plaque.

Experts describe Abbott’s device as an important step in finding a better approach to treating the leading cause of death in the U.S.

“This is presumably a better technology going forward, at least that’s the theory, but it will take years to prove,” said Dr. George Vetrovec, professor emeritus at Virginia Commonwealth University. Vetrovec was part of an FDA advisory panel of cardiologists who overwhelmingly endorsed the device in March.

The Absorb stent, already sold in Europe and Asia, is made of a degradable material that’s designed to stay intact for one year then break down over the next two years.

Use of metallic stents surged in the early 2000s as a treatment for people who suffered a heart attack or experienced chest pain caused by clogged arteries that restrict blood flow. They are still implanted in about 850,000 U.S. patients annually.

But doctors have scaled back their use due to safety concerns, insurance cost-cutting and evidence that they are overused. Studies in 2007 and 2008 suggested that stented arteries faced a higher risk of blood clots, potentially triggering heart attack a year or more down the road. Results of another five-year study showed that patients who received stents to treat chest pain fared about as well as those treated with drugs.

Amid these concerns, Abbott and others began developing dissolving stents that would slowly melt away like stitches, presumably reducing complications.

In the company study submitted to the FDA, patients who got Absorb fared about as well as those receiving Abbott’s older metal stent after one year. But heart-related complications were actually slightly higher with Absorb – 7.8 percent of patients, versus 6.1 percent of patients with the metal stent. That 1.7 percent difference is not considered statistically significant.

Other complications with the new device include allergic reactions, infections and internal bleeding.

Researchers who studied Absorb said it may take years before its advantages become clear. Long-term safety results aren’t expected until 2020.

“We have good theoretical reasons to believe that by getting rid of the stent, and allowing the coronary artery to restore its normal shape, that will prevent many of those late events,” said Dr. Gregg Stone, of Columbia University Medical Center, who helped conduct the pivotal trial of Absorb. Stone was not paid by Abbott for his work on the trial.

Some Wall Street analysts are betting that products like Absorb will allow companies to raise prices and boost revenue.

“The key for the stent market will be whether pricing returns to rational levels and the success of the new bio-absorbable stent platforms,” states Evercore ISI analyst Vijay Kumar, in an investment note. He says a “perfect storm of events,” including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.

Stent sales fell roughly 30 percent to $4.1 billion in 2014 from 2006 levels, according to Evercore.

Abbott said it does not disclose the price of its stents. However, hospitals often bill $30,000 for stenting procedures, which includes the costs of the stent, medical staff and other equipment and services.

Chicago-based Abbott controls a little more than a third of the U.S. stent market. More than a dozen medical device makers are working on their own dissolving stent technologies.

—

AP Medical Writer Linda A. Johnson contributed to this story


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50